A5056508114- Vasculitis and related conditions
- Sarcoidosis and Beryllium Toxicity Research
- Renal Diseases and Glomerulopathies
- Otitis Media and Relapsing Polychondritis
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Urticaria and Related Conditions
- Heparin-Induced Thrombocytopenia and Thrombosis
- Systemic Sclerosis and Related Diseases
- Angiogenesis and VEGF in Cancer
- Atherosclerosis and Cardiovascular Diseases
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Erythropoietin and Anemia Treatment
- Inflammasome and immune disorders
- Nephrotoxicity and Medicinal Plants
- Systemic Lupus Erythematosus Research
- Rheumatoid Arthritis Research and Therapies
- Electrolyte and hormonal disorders
- Complement system in diseases
- Renal and Vascular Pathologies
- Pregnancy and Medication Impact
- Gout, Hyperuricemia, Uric Acid
- Bipolar Disorder and Treatment
- Inflammatory Myopathies and Dermatomyositis
- Drug-Induced Adverse Reactions
- Acute Kidney Injury Research
Sana Klinikum Offenbach
2016-2025
KfH Kuratorium für Dialyse und Nierentransplantation
2022-2023
Goethe University Frankfurt
2023
Philips (Netherlands)
2017
Medizinische Hochschule Hannover
2000-2011
Heinrich Heine University Düsseldorf
2007
University of Lübeck
1995-2006
Heidelberg University
2006
University Hospital Heidelberg
2006
University Hospital Ulm
2006
The primary systemic vasculitides usually associated with autoantibodies to neutrophil cytoplasmic antigens include Wegener's granulomatosis and microscopic polyangiitis. We investigated whether exposure cyclophosphamide in patients generalized vasculitis could be reduced by substitution of azathioprine at remission.
Objectives: To develop European League Against Rheumatism (EULAR) recommendations for the management of small and medium vessel vasculitis. Methods: An expert group (consisting 10 rheumatologists, 3 nephrologists, 2 immunologists, internists representing 8 countries USA, a clinical epidemiologist representative from drug regulatory agency) identified topics systematic literature search using modified Delphi technique. In accordance with standardised EULAR operating procedures, were derived...
Background: Current therapies for antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis are limited by toxicity. Objective: To compare pulse cyclophosphamide with daily oral induction of remission. Design: Randomized, controlled trial. Random assignments were computer-generated; allocation was concealed faxing centralized treatment assignment to providers at the time enrollment. Patients, investigators, and assessors outcomes not blinded assignment. Setting: 42 centers in 12...
The aim of the present study was to detect circulating tumor cells (CTCs) in peripheral blood patients with non-metastatic colon cancer and evaluate whether there is a diurnal variation CTC counts. Furthermore, aimed examine correlation between CTCs TNM stage, other paraclinical variables prognosis.Blood samples were collected from 20 consecutive stage I-III at four different perioperative time points. Detection performed using immunological assay CellSearch®.CTCs detected 1 out 60...
Abstract Objective Standard therapy for antineutrophil cytoplasmic antibody–associated systemic vasculitis (AASV) with cyclophosphamide (CYC) and prednisolone is limited by toxicity. This unblinded, prospective, randomized, controlled trial was undertaken to determine whether methotrexate (MTX) could replace CYC in the early treatment of AASV. Methods Patients newly diagnosed AASV, serum creatinine levels <150 μmoles/liter, without critical organ manifestations disease were randomized...
Objective To examine the outcome in 155 consecutive patients with Wegener's granulomatosis (WG) followed up for a median of 7 years. Methods Treatment was adapted to activity and extent disease, regular evaluation by an interdisciplinary team accompanied group education about vasculitis. Results The estimated survival time 21.7 years (95% confidence interval [95% CI] 15.60–27.86). Twenty-two died; 19 deaths were attributable WG and/or its treatment. Significant predictors at diagnosis age...
Objectives: To develop European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis. Methods: An expert group (10 rheumatologists, 3 nephrologists, 2 immunolgists, internists representing 8 countries and USA, a clinical epidemiologist representative from drug regulatory agency) identified 10 topics systematic literature search through modified Delphi technique. In accordance with standardised EULAR operating procedures, were derived absence...
<h3>Context</h3>Current remission maintenance therapies for antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) are limited by partial efficacy and toxicity.<h3>Objective</h3>To compare the effects of mycophenolate mofetil with azathioprine on prevention relapses in patients AAV.<h3>Design, Setting, Participants</h3>Open-label randomized controlled trial, International Mycophenolate Mofetil Protocol to Reduce Outbreaks Vasculitides (IMPROVE), test hypothesis that is more...
Background— Statins may exert important pleiotropic effects, ie, improve endothelial function, independently of their impact on LDL cholesterol. In humans, however, effects statins have never been unequivocally demonstrated because prolonged statin treatment always results in reduced cholesterol levels. We therefore tested the hypothesis that similar reductions with simvastatin and ezetimibe, a novel absorption inhibitor, result different function. Methods Results— Twenty patients chronic...
<h3>Introduction</h3> The previously reported randomised controlled trial of a consensus regimen pulse cyclophosphamide suggested that it was as effective daily oral (DO) for remission induction antineutrophil cytoplasm autoantibodies-associated systemic vasculitis when both were combined with the same glucocorticoid protocol (CYCLOPS study (Randomised versus Cyclophosphamide therapy ANCA-associated Systemic Vasculitis published de groot K, harper L <i>et al</i> Ann Int Med 2009)). had...
Objective To contrast the effect of burden vasculitis activity with adverse events on 1-year mortality patients antineutrophil cytoplasmic antibody-associated (AAV). Methods This study assessed outcome and in prospectively recruited to four European AAV clinical trials. Data 524 newly diagnosed were included. The was quantified using a severity score for leucopenia, infection other events, an additional weighting follow-up duration. A ‘combined events’ (CBOE) generated each patient by...
<h3>Objectives</h3> A prospective randomised trial to compare two different durations of maintenance immunosuppressive therapy for the prevention relapse in anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV). <h3>Methods</h3> Patients with AAV were recruited 18–24 months after diagnosis if they stable remission cyclophosphamide/prednisolone-based induction followed by azathioprine/prednisolone therapy. They (1:1) receive continued 48 from (continuation group) or...
The number of circulating endothelial progenitor cells (EPCs) correlates with dysfunction and cardiovascular risk in humans. We explored whether angiotensin II receptor antagonist therapy affects the regenerative EPCs patients type 2 diabetes. In a prospective double-blind parallel group study, we randomly treated 18 diabetics olmesartan (40 mg) or placebo for 12 weeks. analyzed CD34+ hematopoietic (flow cytometry) (in vitro assay) before after therapy. verified results second open trial...
Results from open-label trials suggest that methotrexate (MTX) and leflunomide (LEF) are effective for maintenance of remission in Wegener's granulomatosis (WG), but data randomized controlled clinical trails not yet available.In this multicentre, prospective trial, patients with generalized WG were treated either oral LEF 30 mg/day or MTX (starting 7.5 mg/week reaching 20 after 8 weeks) 2 yrs following induction cyclophosphamide. The primary endpoint was the incidence relapses. Secondary...
To assess the frequency and type of neurologic involvement in a cohort patients with generalized Wegener granulomatosis (WG).In prospective analysis clinical, electrophysiologic, radiological, serologic data 128 have been studied over median observation period 19 months (range, 1-60 months).Sixty-four (50%) revealed central or peripheral nervous system involvement. Peripheral neuropathy (PN) affected 56 patients, 9 cases was involved, 6 cranial nerves were involved. Thirty-one showed distal...
To compare the efficacy of low-dose intravenous (IV) methotrexate (MTX; 0.3 mg/kg once weekly), both with and without concomitant prednisone, versus daily oral trimethoprim/sulfamethoxazole (T/S; 160 mg trimethoprim + 800 sulfamethoxazole twice a day), in maintaining remission patients generalized Wegener's granulomatosis (WG).In this study, 65 WG whose disease had entered cyclophosphamide (CYC) prednisone therapy were started on one following remission-maintenance regimens: MTX alone (group...
The hematopoietic cytokine erythropoietin has cytoprotective effects in endothelial cells vitro that are mediated through direct activation of the pro-survival Akt tyrosine kinase signaling pathway. We tested hypothesis low-dose therapy with long-acting recombinant human analogue darbepoetin alpha protects vascular endothelium vivo a classic remnant kidney rat model characterized by severe damage, progressive sclerosis, and ischemia-induced tissue fibrosis.Using parallel group study design,...
The NORAM (Nonrenal Wegener's Granulomatosis Treated Alternatively with Methotrexate [MTX]) trial demonstrated that MTX can replace cyclophosphamide (CYC) as remission-inducing treatment for patients newly diagnosed early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Duration of relapse-free survival was longer among CYC-treated than MTX-treated during short-term followup. aim the present study to describe long-term outcome in enrolled randomized clinical trial.Outcome...